Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study.
Hallmer F , Andersson G , Götrick B , Warfvinge G , Anderud J , Bjørnland T 
Oral Surg Oral Med Oral Pathol Oral Radiol.2018 Aug 31 ; ():.
PubMedで表示
Google翻訳で開く
(25view , 0users)
Full Text Sources
Medication-related osteonecrosis of the jaw (MRONJ) has a wide range of prevalence, and a standard therapy has not yet been established. The aim of this study was to analyze the prevalence and initiating factors of MRONJ and the outcomes of surgical therapy.
PMID: 30249535 [PubMed - as supplied by publisher]
PMID: 30249535 [PubMed - as supplied by publisher]
関連論文
- [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
- Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab.
- Interventions for managing medication-related osteonecrosis of the jaw.
- Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report.
- [Review] Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study.